When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
STSA - Satsuma Pharma's STS101 flunks late-stage migraine study shares down 84%
Satsuma Pharmaceuticals Inc.
Thinly traded micro cap Satsuma Pharmaceuticals (NASDAQ:STSA) tanks 84% premarket on robust volume in reaction to an unsuccessful Phase 3 EMERGE efficacy trial evaluating STS101 (dihydroergotamine) (DHE) as an acute treatment for migraine.
More news on: Satsuma Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,